Analyzing Evolus (NASDAQ:EOLS) and Lonza Group (OTCMKTS:LZAGY)

Lonza Group (OTCMKTS:LZAGY) and Evolus (NASDAQ:EOLS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, risk, dividends, institutional ownership and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Lonza Group and Evolus, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lonza Group	0	1	1	0	2.50
Evolus	1	1	4	0	2.50

Evolus has a consensus price target of $16.00, suggesting a potential upside of 179.23%. Given Evolus’ higher probable upside, analysts plainly believe Evolus is more favorable than Lonza Group.

Institutional and Insider Ownership

0.0% of Lonza Group shares are held by institutional investors. Comparatively, 90.7% of Evolus shares are held by institutional investors. 0.1% of Lonza Group shares are held by company insiders. Comparatively, 5.0% of Evolus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Lonza Group and Evolus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lonza Group	N/A	N/A	N/A
Evolus	-14.39%	N/A	-19.03%

Volatility and Risk

Lonza Group has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500. Comparatively, Evolus has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500.

Earnings and Valuation

This table compares Lonza Group and Evolus”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lonza Group	$7.88 billion	6.25	$1.15 billion	N/A	N/A
Evolus	$297.18 million	1.27	-$51.64 million	($0.67)	-8.55

Lonza Group has higher revenue and earnings than Evolus.

About Lonza Group

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.

About Evolus

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.